September 12, 2018
Bayer Animal Health GmbH and NeuroCycle Therapeutics, Inc. (NCT) have signed a global license agreement to advance innovative allergy treatment options for companion animals. As part of the license agreement, Bayer will develop and commercialize novel compounds based on knowledge and intellectual property licensed and controlled by NCT.
Massachusetts Life Sciences Innovation Day
Poster Presentation, Boston, MA
May 31, 2018
NeuroCycle Therapeutics, Inc. was selected to exhibit a poster at the Massachusetts Life Sciences Innovation (MALSI) Day on May 31, 2018. The event was billed as "the flagship event of life sciences in Massachusetts, jointly and actively put together by all the major organizations that are involved in starting and supporting the life sciences start-up ecosystem in the Commonwealth," we appreciated the opportunity to meet the people who make the Life Sciences such an exciting field.
Life Sciences Global Pitch Fest!
Pitch Presentation, Cambridge, MA
May 31, 2018
Jed Hubbs, Ph.D. and CEO of NeuroCycle Therapeutics participated in the Life Sciences Global Pitch Fest at the Novartis Institutes for BioMedical Research (NIBR) in Kendall on May 31, 2018. Every entrepreneur had 1 minute and 1 slide to present.
1st European Biotech Day with LabCentral
Presentation, Cambridge, MA
June 4, 2018
Jed Hubbs, Ph.D. and CEO of NeuroCycle Therapeutics gave a short presentation at the 1st European Biotech Day at LabCentral in Cambridge, MA. Hosted by the German Accelerator Life Sciences and LabCentral, the event featured panel discussions and a pitch competition from U.S. and European startups.